Schedule 13D ownership disclosure
Apogee Therapeutics Inc
Common Stock, $0.00001 par value · CUSIP: 03770N101
Event date: 2026-03-26
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Fairmount Funds Management LLCReported CIK 0001802528
Shares: 6,666,332.00 · Class: 9.84%
- Fairmount Healthcare Fund II L.P.Reported CIK 0001769651
Shares: 6,666,332.00 · Class: 9.84%
- Peter Evan HarwinReported CIK 0001663607
Shares: 6,764,974.00 · Class: 9.99%
- Tomas KiselakReported CIK 0001830177
Shares: 6,764,974.00 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-26-036265
- Form type
- SCHEDULE 13D/A
- Filer
- Apogee Therapeutics, Inc.
- CIK
- CIK 1974640
- Filed
- Mar 27, 2026
- Reporting period
- Mar 26, 2026
- Description
- Schedule 13D beneficial ownership